Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ETF | ETFs | 31/08/24 | 42 | 27K | |||
|
|||||||
ETF | Ann: Removal from Trading Status | 01/07/20 | 0 | 900 | |||
|
|||||||
ETF | Ann: Completion of Termination Payment | 30/06/20 | 0 | 338 | |||
|
|||||||
ETF | Ann: Suspension from Trading Status - UBS ETFs | 11/05/20 | 0 | 583 | |||
|
|||||||
ETF | Ann: Month end units on issue | 08:34 | 0 | 404 | |||
|
|||||||
ETF | Ann: Month end units on issue | 02/04/20 | 0 | 444 | |||
|
|||||||
ETF | Ann: Termination of UBS exchange traded fund ETF | 13/03/20 | 0 | 572 | |||
|
|||||||
ETF | Ann: Interim Financial Report | 13/03/20 | 0 | 383 | |||
|
See All Discussions